Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Gender Difference In Stroke: One Disease, Two Effects:
Congress is expected to take up legislation this summer aimed at improving the nation"s healthcare system. Whatever the shape of the final bill, it will have at least some impact on one of the three leading causes of death in the U.S.: stroke.
generic viagra online
New Study Shows Boys Face Serious Issues Which Are Being Ignored
Both boys and girls have issues, but boys seem to be the ones getting the raw deal. According to Judith Kleinfeld, professor of psychology at the University of Alaska Fairbanks in the US, issues affecting boys are more serious than those affecting girls, but they have been neglected by policy makers. Her review1 of issues characterizing American boyhood, how they compare to those affecting girls, and the lack of initiatives in place to address them has just been published in the June issue of Springer"s journal Gender Issues.
News of the day
Additional "Unsuspected" Breast Cancers Not Seen On Mammography Or Ultrasound Detected By Breast MRI
A total of 199 patients with newly diagnosed breast cancer underwent breast MRI. "We found additional, unsuspected cancers in the ipsilateral breast (the one that had already been diagnosed with cancer) in 16% of patients; we found cancers in the contralateral breast (the one that had not been diagnosed with cancer) in 4% of patients," said Petra J. Lewis, MD, lead author of the study. "These patients had already had bilateral mammography and these tumors had not been apparent on mammography," said Dr. Lewis.
Diagnostics

CHMP Recommends Expanded Use Of ISENTRESS(R) (Raltegravir), From MSD, In Adult Patients With HIV-1 Infection

Merck Sharp & Dohme Limited (MSD) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending expanded marketing authorisation for "Isentress" (raltegravir) in combination with other antiretroviral (ARV) medicinal products for the treatment of HIV-1 infection in all appropriate adult patients, including patients starting HIV therapy for the first time (treatment-naç¯ve), as well as treatment-experienced patients. The positive opinion will be reviewed by the European Commission, which grants marketing authorisation to the 27 countries that are members of the European Union (EU), as well as Iceland and Norway. Raltegravir, the first and only approved integrase inhibitor, is currently approved in more than 80 countries across six continents for use in combination with other ARV agents for the treatment of HIV-1 infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing ARV therapy1. If marketing authorisation is granted by the European Commission, the drug will be approved for use both in treatment-naç¯ve and treatment-experienced patients. About Raltegravir Raltegravir works by inhibiting the insertion of HIV-1 DNA into human DNA by the integrase enzyme and has demonstrated rapid antiviral activity2. Inhibiting integrase from performing this essential function limits the ability of the virus to replicate and infect new cells2. There are drugs in use that inhibit two other enzymes critical to the HIV-1 replication process - protease and reverse transcriptase - but raltegravir is the only drug approved that inhibits the integrase enzyme3. Raltegravir is a single 400 mg tablet taken twice daily without regard to food. Raltegravir does not require boosting with ritonavir1. References 1. Summary of Product Characteristics 2. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and Efficacy of the HIV-1 Integrase Inhibitor Raltegravir (MK-0518) in Treatment-Experienced Patients with Multidrug-Resistant Virus: A Phase II Randomised Controlled Trial. The Lancet 2007; 369:1261-1269. 3. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646-50. Merck Sharp & Dohme Limited


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009